Lund University and Skåne University Hospital published first human results showing that transplanting cryopreserved stem-cell-derived dopamine progenitors into people with Parkinson’s disease is feasible and safe. The Phase I/II open-label, multicenter, single-arm dose-escalation trial enrolled eight participants in the STEM-PD program. In the Nature Medicine report, the investigators reported no serious side effects linked to the transplanted cells during the first year of follow-up. The trial is designed to evaluate safety and feasibility while building evidence for continued clinical development of off-the-shelf dopaminergic progenitor cell products. The publication positions STEM-PD as a milestone for regenerative medicine in Parkinson’s, with the next steps expected to include larger cohorts to evaluate therapeutic potential and longer-term risks.